Zeev Estrov MD

PubMed

• CLL cell-derived exosomes alter the immune and hematopoietic systems.
  Ivo Veletic, David M Harris, Uri Rozovski, Maria Teresa S Bertilaccio, George A Calin
  Leukemia. 2025-04-04
• The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers.
  Recep Bayraktar, Yitao Tang, Mihnea P Dragomir, Cristina Ivan, Xinxin Peng
  Science Advances. 2025-02-21
• 9 citations
  Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
  Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D Bledsoe, Naval G Daver
  Haematologica. 2024-08-01

Abstracts/Posters

• Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/9/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Periphera...
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pt...
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• STAT3-Induced Gli1 Promotes the Differentiation and Maturation of Myelofibrosis Fibrocytes
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
  Zeev E. Estrov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of Cytogenetic Stratifications in Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Bone Marrow Fibrocytes Overexpress Gli1 Oncogenic Transcription Factor in Primary Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all

Other

• Clinical use of minimal residual disease detection in acute lymphoblastic leukemia 
  Estrov Z, Stock W
  http://www.uptodate.com/contents/clinical-use-of-minimal-residual-disease-detection-in-acute-lymphob
  UpToDate, Wolters Kluwer Health - 2013-04-03
• Detection of minimal residual disease in acute lymphoblastic leukemia 
  Estrov Z, Stock W
  http://www.uptodate.com/contents/detection-of-minimal-residual-disease-in-acute-lymphoblastic-leukem
  UpToDate, Wolters Kluwer Health - 2012-02-07